The nature and order of testing are largely dictated by cost and resource availability; for example, even though the diagnostic efficacy of CA125 is low [24], it remains recommended under the National Institute for Health and Care Excellence (NICE) guidelines in England and Wales for first-line investigation as part of the “2-week wait suspected cancer pathway” [5,25]. The gene discussed is MUC16; the disease is cancer.